Orum Therapeutics, Inc. Logo

Orum Therapeutics, Inc.

Clinical-stage biotech developing degrader-antibody conjugates to treat cancer.

475830 | KO

Overview

Corporate Details

ISIN(s):
KR7475830006
LEI:
Country:
South Korea
Address:
대전광역시 유성구 문지로 281-25, 대전광역시

Description

Orum Therapeutics is a clinical-stage biotechnology company that develops targeted protein degradation (TPD) therapeutics. The company's proprietary TPD²® platform creates a novel class of antibody-drug conjugates (ADCs), referred to as degrader-antibody conjugates (DACs). This technology combines the cell-targeting precision of antibodies with the catalytic action of protein degraders. The approach is designed to selectively deliver payloads to diseased cells to eliminate intracellular proteins that are difficult to target with conventional drugs. Orum's primary focus is on developing treatments for cancer, aiming to improve efficacy and safety over existing therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 00:00
주식등의대량보유상황보고서(일반)
Korean 352.9 KB
2025-08-29 00:00
주식등의대량보유상황보고서(일반)
Korean 348.3 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 382.4 KB
2025-08-08 00:00
주식등의대량보유상황보고서(일반)
Korean 339.8 KB
2025-08-01 00:00
임시주주총회결과
Korean 10.7 KB
2025-08-01 00:00
주식매수선택권부여에관한신고
Korean 21.5 KB
2025-07-25 00:00
주식등의대량보유상황보고서(일반)
Korean 368.6 KB
2025-07-17 00:00
주주총회소집공고
Korean 77.7 KB
2025-07-10 00:00
[기재정정]주주총회소집결의
Korean 16.8 KB
2025-06-25 00:00
주주총회소집결의
Korean 10.7 KB
2025-06-25 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-06-04 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 372.2 KB
2025-06-04 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 360.6 KB
2025-05-26 00:00
기업설명회(IR)개최
Korean 6.7 KB

Automate Your Workflow. Get a real-time feed of all Orum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Initiator Pharma A/S Logo
Clinical-stage company developing drugs for central and peripheral nervous system needs.
Denmark
INIT
Inmolecule Nanotech, S.A. Logo
Develops nanoparticles from plant compounds for biomedical and personal care products.
Spain
MLINA
Inotiv, Inc. Logo
A CRO providing nonclinical drug development services and research models.
United States of America
NOTV
IntegraGen Logo
Provides genomic services for cancer and rare diseases, translating research to practice.
France
ALINT
Intellia Therapeutics, Inc. Logo
A clinical-stage genome editing company developing therapeutics using CRISPR/Cas9.
United States of America
NTLA
InterDigital, Inc. Logo
An R&D company licensing foundational technologies for mobile, video, and AI.
United States of America
IDCC
IntoCell, Inc. Logo
Develops platform technologies for Antibody-Drug Conjugates (ADCs) for oncology.
South Korea
287840
Inventage Lab Inc. Logo
Biopharmaceutical company developing advanced drug delivery systems.
South Korea
389470
Investeko Spolka Akcyjna Logo
Specializes in environmental protection and sustainable business solutions.
Poland
IVE
IQVIA HOLDINGS INC. Logo
Provider of analytics, tech solutions, and clinical research for life sciences.
United States of America
IQV

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.